摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

β-D-ribofuranosyl-1-carboximidic acid methyl ester | 62404-62-0

中文名称
——
中文别名
——
英文名称
β-D-ribofuranosyl-1-carboximidic acid methyl ester
英文别名
methyl β-D-ribofuranosyl-1-carboximidate;methyl 2,5-anhydro-D-allonimidate;methyl 2,5-anhydroallonimidate;methyl (2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carboximidate
β-D-ribofuranosyl-1-carboximidic acid methyl ester化学式
CAS
62404-62-0
化学式
C7H13NO5
mdl
——
分子量
191.184
InChiKey
MAXWBUOJXYRZKQ-KVTDHHQDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    369.2±52.0 °C(Predicted)
  • 密度:
    1.62±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.4
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    103
  • 氢给体数:
    4
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    β-D-ribofuranosyl-1-carboximidic acid methyl ester吡啶盐酸 、 Dowex 50W-X8(H+) 、 硫化氢次磷酸 、 sodium nitrite 作用下, 以 甲醇 为溶剂, 反应 18.0h, 生成 2-beta-D-呋喃核糖基-4-噻唑羧酸乙酯
    参考文献:
    名称:
    Synthesis of 4-substituted 5-amino-2-(.beta.-D-ribofuranosyl)thiazoles and 4-substituted 5-amino-2-(.beta.-D-ribofuranosyl)selenazoles, and their respective conversion into 2-(.beta.-D-ribofuranosyl)thiazolo[5,4-d]pyrimidines and 2-(.beta.-D-ribofuranosyl)selenazolo[5,4-d]pyrimidines. A new synthesis of tiazofurin and selenazofurin
    摘要:
    DOI:
    10.1021/jo00210a033
  • 作为产物:
    描述:
    参考文献:
    名称:
    (β-D-呋喃核糖基)甲脒设计和合成 2-(β-D-呋喃核糖基)嘧啶,包括含 RF 的衍生物
    摘要:
    通过(β-D-呋喃核糖基)甲脒与各种介电底物(如 3-烷氧基和 3-)反应合成了多种新型 2-(β-D-呋喃核糖基)嘧啶,包括含 RF 的衍生物。氯-1-(多氟烷基)丙烯-1-酮、3-硝基-和3-(苯乙炔基)色酮和杂芳基炔酮。
    DOI:
    10.1002/ejoc.201300107
点击查看最新优质反应信息

文献信息

  • Procedures for obtaining ribo-C-nucleosides
    申请人:ICN Pharmaceuticals, Inc.
    公开号:US05907036A1
    公开(公告)日:1999-05-25
    Novel procedures for obtaining ribo-C-nucleosides, including especially 2-.beta.-D-ribofuranosylthiazole-4-carboxylamide (tiazofirin) and 2-.beta.-D-ribofuranosylselenazole-4-carboxylamide (sylenazofurin) and synthesis intermediates thereof. The novel procedures involve introducing a cyano group at the 1' position of a ribose, directly or indirectly converting the cyano group to HN.dbd.C--OR.sub.1 or thicarboxylamide wherein R.sub.1 is a lower alkyl, forming the group which substituted for the cyano group into a heterocyclic ring containing an ester, and converting the ester into an amide.
    获得核糖C核苷的新方法,特别是2-β-D-核糖呋喃噻唑-4-羧酰胺(噻唑呋喃)和2-β-D-核糖呋喃唑-4-羧酰胺(呋喃)及其合成中间体。这些新方法涉及在核糖的1'位置引入基,直接或间接地将基转化为HN.dbd.C--OR.sub.1或代羧酰胺,其中R.sub.1是较低的烷基,将替代基的基团形成一个含有酯的杂环环,并将酯转化为酰胺。
  • Synthesis of 2-(β-D-ribofuranosyl)pyrimidines, A new class of<i>C</i>-nucleosides
    作者:Timothy A. Riley、William J. Hennen、N. Kent Dalley、Bruce E. Wilson、Roland K. Robins、Steven B. Larson
    DOI:10.1002/jhet.5570240413
    日期:1987.7
    A new C-glycosyl precursor for C-nucleoside synthesis, 2,5-anhydroallonamidine hydrochloride (4) was prepared and utilized in a Traube type synthesis to prepare 2-(β-D-ribofuranosyl)pyrimidines, a new class of C-nucleosides. The anomeric configuration of 4 was confirmed by single-crystal X-ray analysis. Reaction of 4 with ethyl acetoacetate gave 6-methyl-2-(β-D-ribofuranosyl)pyrimidin-4-(1H)-one (5)
    制备了一种新的用于C-核苷合成的C-糖基前体2,5,5-脱氢lon啶盐酸盐(4),并用于Traube型合成中制备了2-(β-D-核呋喃呋喃糖基)嘧啶,一类新的C-核苷。 。通过单晶X射线分析确认了4的异头构型。4与乙酰乙酸乙酯的反应得到6-甲基-2-(β-D-呋喃呋喃糖基)嘧啶-4-(1 H)-一(5)。4与草酰二乙酸乙酯反应,得到2-(β-D-呋喃呋喃糖基)嘧啶-6(1 H)-氧-4-羧酸(6)。酯化6用氯化氢乙醇溶液得到相应的酯7,当用乙醇氨水处理时,得到2-(β-D-呋喃呋喃糖基)嘧啶-6(1H)-氧代-4-羧酰胺(8)。将2,5-脱氢lon啶盐酸盐(4)与4-(二甲基基)-2-氧代-3-丁烯酸乙酯(9)缩合,得到2-(β-D-呋喃呋喃糖基)嘧啶-4-羧酸乙酯(10)。用乙醇处理10,得到2-(β-D-呋喃呋喃糖基)嘧啶-4-羧酰胺(11)。单晶X射线分析证实了11的β-异
  • Synthesis and pharmacological evaluation of a series of analogs of 1-methylisoguanosine
    作者:Robert T. Bartlett、Alan F. Cook、Michael J. Holman、Warren W. McComas、Eugene F. Nowoswait、Mohindar S. Poonian、Judy A. Baird-Lambert、Brian A. Baldo、John F. Marwood
    DOI:10.1021/jm00140a007
    日期:1981.8
    Modification at the 5' position yielded the deoxy, iodo, and phosphate derivatives 15, 13, and 16, as well as the cyclic 3',5'-phosphate 17. The synthesis of the C-nucleoside analogue 19 was achieved from the beta-D-ribofuranosylcarboximidic ester 20. The acyclic analogue 29 and the beta-D-arabinofuranosyl derivative 35 were both synthesized by reaction of methyl isocyanate with the appropriately protected
    在肌肉松弛剂,心血管,抗炎和抗过敏试验中,评估了具有药理活性的海洋天然产物1-甲基异鸟苷(1)的一系列类似物的生物活性。在1位上的修饰分别产生乙基,正丁基,正辛基和苯基衍生物3-6。在8位的取代提供了氨基化合物9-11。在5'位的修饰产生了脱氧,磷酸盐衍生物15、13和16,以及环状3',5'-磷酸盐17。C-核苷类似物19的合成由β完成-D-呋喃核糖基羧酰亚胺酯20。无环类似物29和β-D-阿拉伯呋喃糖基衍生物35都是通过异氰酸甲酯与适当保护的咪唑前体28和32反应合成的。1-甲基黄嘌呤(12),异鸟苷(7)和2-甲氧基腺苷(18)。也被合成。在高达100 mg / kg po的剂量下,5'-磷酸16,环状3',5'-磷酸17和O-甲基化的类似物2-甲氧基腺苷18在产生肌肉松弛和体温过低方面具有活性。这些化合物具有抗过敏活性,并且与1-乙基(3)和1-正丁基(4)类似物
  • Non-natural carbon-linked nucleotides and dinucleotides
    申请人:Mack Robert Stephen
    公开号:US20050009777A1
    公开(公告)日:2005-01-13
    Nucleotide derivatives of formula (1) are described, wherein: G is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, aromatic or heteroaromatic group or a non natural carbon-linked nucleoside as defined herein; G′ is a non-natural carbon-linked nucleoside as defined herein; n is zero, or the integer 1 or 2; m is zero or the integer 1 or 2; and the salts, solvates, hydrates and N-oxides thereof. The compounds are P2Y receptor agonists and are of use in the prophylaxis and treatment of diseases and disorders involving abnormal secretory mechanisms such as inadequate functioning of mucociliary clearance mechanisms or abnormal tear secretion or in the treatment of diseases involving inappropriate cellular glucose uptake.
    本文描述了式(1)的核苷酸衍生物,其中:G是氢原子或可选取代的脂肪族,杂脂族,环脂族,多环脂族,芳香族或杂芳香族基团或非天然的碳链核苷酸,如本文所定义;G'是本文所定义的非天然碳链核苷酸;n为零或整数1或2;m为零或整数1或2;以及其盐,溶剂合物,合物和N-氧化物。这些化合物是P2Y受体激动剂,可用于预防和治疗涉及异常分泌机制的疾病和障碍,例如粘液纤毛清除机制的功能不足或泪液分泌异常,或用于治疗涉及不适当细胞葡萄糖摄取的疾病。
  • A novel precursor for the synthesis of C-nucleoside analogs. Synthesis of the C-nucleoside analogs of ribavirin, bredinin, and related compounds
    作者:Mohindar S. Poonian、Eugene F. Nowoswiat
    DOI:10.1021/jo01290a002
    日期:1980.1
查看更多